Division of Mylan NV
Latest From Viatris GmbH
Hours before the US FDA confirmed the first drug shortage due to active pharmaceutical ingredient constraints because of the coronavirus situation in China, generics industry leader Mylan came under pressure about the potential impact on its business.
Pfizer's biosimilars franchise is well on its way to becoming a blockbuster business, three years after the company launched its first US biosimilar.
Pfizer's biosimilar franchise is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.
By merging to create Viatris, Mylan and Pfizer’s Upjohn unit intend to occupy a space between generics players and big pharma by offering a broad array of affordable products all around the world.
- Medical Devices
- Drug Delivery
- Therapeutic Areas
- Asta Medica AG
- Western Europe
- Parent & Subsidiaries
- Mylan NV
- Senior Management
Markus Peterseim, CEO
Paul Taaffe, CFO
Harald Borbe, CSO
Dirk Groen, SVP, Strategic Mktg. & Bus. Dev.
- Contact Info
Phone: (49) 69 4001 2812
P.O. Box 100105 Frankfurt am Main, D-60314
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.